143883-74-3

Basic information

• Product Name: 6-phenyl-3,9-dimethoxy-1,2-methylenedioxy-10,11-methylenedioxy-6,7-dihydro-5H-dibenz[c,e]azepine
• CAS NO: 143883-74-3
• Molecular Weight: 419.434
• Mol File: 143883-74-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 6-phenyl-3,9-dimethoxy-1,2-methylenedioxy-10,11-methylenedioxy-6,7-dihydro-5H-dibenz[c,e]azepine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-phenyl-3,9-dimethoxy-1,2-methylenedioxy-10,11-methylenedioxy-6,7-dihydro-5H-dibenz[c,e]azepine(143883-74-3)
• EPA Substance Registry System: 6-phenyl-3,9-dimethoxy-1,2-methylenedioxy-10,11-methylenedioxy-6,7-dihydro-5H-dibenz[c,e]azepine(143883-74-3)

Safety Data

• Hazardous Substances Data: 143883-74-3(Hazardous Substances Data)

Upstream product

• 3934-84-7 3,4-dihydroxy-5-methoxybenzoic acid 
• 111897-19-9 DDB 
• 90749-17-0 4,4'-dimethoxy-5,6,5',6'-dimethylenedioxy-2,2'-dibenzyl alcohol 
• 123685-25-6 5-methoxy-3,4-dihydroxy-2-bromobenzoic acid methyl ester 
• 143883-73-2 2-bromo-5-O-methyl gallic acid 
• 149-91-7 3,4,5-trihydroxybenzoic acid 
• 81474-46-6 4-bromo-7-methoxybenzo[1,3]dioxole-5-carboxylic acid methyl ester 
• 135261-37-9 4,4'-dimethoxy-5,6,5',6'-dimethylenedioxy-2,2'-dibenzyl chloride 
• 62-53-3 aniline 

Relevant articles and documents

Synthesis and biological evaluation of novel bifendate derivatives bearing 6,7-dihydro-dibenzo[c,e]azepine scaffold as potent P-glycoprotein inhibitors

Overexpression of P-glycoprotein (P-gp) is one of the major problems in successful treatment of cancers. To find new P-gp inhibitors, a series of bifendate (DDB) derivatives bearing dibenzo[c,e]azepine scaffold were synthesized and evaluated. Compound 4i more potently reversed P-gp-mediated multidrug resistance (MDR) than DDB and verapamil (VRP) by blocking P-gp mediated drug efflux function and increasing drug accumulation in K562/A02 MDR cells, and persisted longer chemo-sensitizing effect (>24 h) than VRP (6 h). Interestingly, unlike VRP, 4i showed no stimulation on the P-gp ATPase activity, suggesting it is not a substrate of P-gp. Given the low intrinsic cytotoxicity of 4i in vitro, it may represent a promising lead for developing therapeutics targeting P-gp-mediated MDR in combinational cancer chemotherapy.